Regeneron Pharmaceuticals, Inc. (REGN)
Current
- (-)
After Hours
Rating Performance
Rating Return
+0.0% vs
Rating Accuracy
0% (0 of 0*)
Rating Return
+6.39% vs
Rating Accuracy
100.0% (1 of 1*)
Rating Return
+6.39% vs
Rating Accuracy
100.0% (1 of 1*)
Rating Return
-12.09% vs
Rating Accuracy
0% (0 of 1*)
FV Performance
FV Accuracy
11 Hits (157.14% Hit Rate)
FV Avg. Distance
+6.04%
FV Accuracy
11 Hits (122.22% Hit Rate)
FV Avg. Distance
+7.12%
FV Accuracy
11 Hits (57.89% Hit Rate)
FV Avg. Distance
+7.12%
FV Accuracy
54 Hits (125.58% Hit Rate)
FV Avg. Distance
+2.15%
*There is a current rating on the stock that is included in these numbers based on its performance so far
About
CEO
Leonard S. Schleifer
Employees
8,100
Industry
Ophthalmology Biopharmaceuticals
Sector
Healthcare
Headquarters
Tarrytown
Exchange
NASDAQ
Website
http://www.regeneron.comSummary Stats
Market Cap
80.4B
Revenue
13.7B
Net Income
5.37B
EPS
$47.37
Price-to-Earnings
15.86
Price-to-Book
3.75
Debt-to-Equity
0.29
News
Analyst Ratings
Price targets projected by 22 analysts
High
$793.00
Average
$673.86
Low
$550.00
Ratings calculated by 26 analysts
Buy
15
Hold
11
Sell
0
Last Dividend
Amount
-
Dividend Date
-
Frequency
-
Dividend Yield
Earnings
Most Recent Earnings
Last Earnings for Q4 2022
Above by $2.53
$12.56 +25.2%
10.03
23.72
Down 47%
Actual vs Estimates
XX
xxx
Upcoming Estimates Unavailable
-
-
-
--